These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30257587)

  • 21. Deiodinases, Organic Anion Transporter Polypeptide Polymorphisms, and Thyroid Hormones in Patients with Myocardial Infarction.
    Brozaitiene J; Skiriute D; Burkauskas J; Podlipskyte A; Jankauskiene E; Serretti A; Mickuviene N
    Genet Test Mol Biomarkers; 2018 Apr; 22(4):270-278. PubMed ID: 29641285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Type 2 deiodinase polymorphism causes ER stress and hypothyroidism in the brain.
    Jo S; Fonseca TL; Bocco BMLC; Fernandes GW; McAninch EA; Bolin AP; Da Conceição RR; Werneck-de-Castro JP; Ignacio DL; Egri P; Németh D; Fekete C; Bernardi MM; Leitch VD; Mannan NS; Curry KF; Butterfield NC; Bassett JHD; Williams GR; Gereben B; Ribeiro MO; Bianco AC
    J Clin Invest; 2019 Jan; 129(1):230-245. PubMed ID: 30352046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Type 2 deiodinase and host responses of sepsis and acute lung injury.
    Ma SF; Xie L; Pino-Yanes M; Sammani S; Wade MS; Letsiou E; Siegler J; Wang T; Infusino G; Kittles RA; Flores C; Zhou T; Prabhakar BS; Moreno-Vinasco L; Villar J; Jacobson JR; Dudek SM; Garcia JG
    Am J Respir Cell Mol Biol; 2011 Dec; 45(6):1203-11. PubMed ID: 21685153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters.
    Peeters RP; van den Beld AW; Attalki H; Toor Hv; de Rijke YB; Kuiper GG; Lamberts SW; Janssen JA; Uitterlinden AG; Visser TJ
    Am J Physiol Endocrinol Metab; 2005 Jul; 289(1):E75-81. PubMed ID: 15727947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between genetic polymorphism and levothyroxine bioavailability in hypothyroid patients.
    Arici M; Oztas E; Yanar F; Aksakal N; Ozcinar B; Ozhan G
    Endocr J; 2018 Mar; 65(3):317-323. PubMed ID: 29321381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. D2 Thr92Ala and PPARγ2 Pro12Ala polymorphisms interact in the modulation of insulin resistance in type 2 diabetic patients.
    Estivalet AA; Leiria LB; Dora JM; Rheinheimer J; Bouças AP; Maia AL; Crispim D
    Obesity (Silver Spring); 2011 Apr; 19(4):825-32. PubMed ID: 20930717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of DIO2 and MCT10 Polymorphisms With Persistent Symptoms in LT4-Treated Patients in the UK Biobank.
    Jensen CZ; Isaksen JL; Ahlberg G; Olesen MS; Nygaard B; Ellervik C; Kanters JK
    J Clin Endocrinol Metab; 2024 Jan; 109(2):e613-e622. PubMed ID: 37740545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Type 2 iodothyronine deiodinase in skeletal muscle: effects of hypothyroidism and fasting.
    Heemstra KA; Soeters MR; Fliers E; Serlie MJ; Burggraaf J; van Doorn MB; van der Klaauw AA; Romijn JA; Smit JW; Corssmit EP; Visser TJ
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2144-50. PubMed ID: 19293265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe.
    de Jong FJ; Peeters RP; den Heijer T; van der Deure WM; Hofman A; Uitterlinden AG; Visser TJ; Breteler MM
    J Clin Endocrinol Metab; 2007 Feb; 92(2):636-40. PubMed ID: 17105838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thr92Ala polymorphism in the type 2 deiodinase gene: an evolutionary perspective.
    Ricci C; Kakularam KR; Marzocchi C; Capecchi G; Riolo G; Boschin F; Kuhn H; Castagna MG; Cantara S
    J Endocrinol Invest; 2020 Dec; 43(12):1749-1757. PubMed ID: 32436183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density.
    Heemstra KA; Hoftijzer H; van der Deure WM; Peeters RP; Hamdy NA; Pereira A; Corssmit EP; Romijn JA; Visser TJ; Smit JW
    J Bone Miner Res; 2010 Jun; 25(6):1385-91. PubMed ID: 20200941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Type 2 deiodinase Thr92Ala polymorphism is associated with a reduction in bone mineral density: A community-based korean genome and epidemiology study.
    Kang YE; Kang YM; Park B; Shong M; Yi HS
    Clin Endocrinol (Oxf); 2020 Sep; 93(3):238-247. PubMed ID: 32324283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional analysis of novel genetic variation in the thyroid hormone activating type 2 deiodinase.
    Zevenbergen C; Klootwijk W; Peeters RP; Medici M; de Rijke YB; Huisman SA; Goeman H; Boot E; de Kuijper G; de Waal KH; Meima ME; Larsen PR; Visser TJ; Visser WE
    J Clin Endocrinol Metab; 2014 Nov; 99(11):E2429-36. PubMed ID: 25140401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Type II 5' Monodeiodinase Thr92Ala Single Nucleotide Gene Polymorphism and Circulating Thyroid Hormones Among Type 2 Diabetes Mellitus Patients.
    Yalakanti D; Dolia PB
    Indian J Clin Biochem; 2016 Apr; 31(2):152-61. PubMed ID: 27069323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetics in endocrinology: genetic variation in deiodinases: a systematic review of potential clinical effects in humans.
    Verloop H; Dekkers OM; Peeters RP; Schoones JW; Smit JW
    Eur J Endocrinol; 2014 Sep; 171(3):R123-35. PubMed ID: 24878678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The type 2 deiodinase ORFa-Gly3Asp polymorphism (rs12885300) influences the set point of the hypothalamus-pituitary-thyroid axis in patients treated for differentiated thyroid carcinoma.
    Hoftijzer HC; Heemstra KA; Visser TJ; le Cessie S; Peeters RP; Corssmit EP; Smit JW
    J Clin Endocrinol Metab; 2011 Sep; 96(9):E1527-33. PubMed ID: 21715540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterozygote Advantage of the Type II Deiodinase Thr92Ala Polymorphism on Intrahospital Mortality of COVID-19.
    de Lima Beltrão FE; de Almeida Beltrão DC; Carvalhal G; de Lima Beltrão FE; de Souza Braga Filho J; de Brito Oliveira J; de Jesus JDS; Machado GJR; Dos Santos Silva H; Teixeira HMP; Rodrigues JL; de Figueiredo CAV; Dos Santos Costa R; Hecht F; Bianco AC; da Conceição Rodrigues Gonçalves M; Ramos HE
    J Clin Endocrinol Metab; 2022 May; 107(6):e2488-e2501. PubMed ID: 35137147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination L-T3 and L-T4 therapy for hypothyroidism.
    Wartofsky L
    Curr Opin Endocrinol Diabetes Obes; 2013 Oct; 20(5):460-6. PubMed ID: 23974776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of thyroid function and polymorphisms in the type 2 deiodinase on blood pressure: the Rotterdam Study and the Rotterdam Scan Study.
    van der Deure WM; Peeters RP; Uitterlinden AG; Hofman A; Breteler MM; Witteman J; Visser TJ
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):137-44. PubMed ID: 19178511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of DIO2 as a new susceptibility locus for symptomatic osteoarthritis.
    Meulenbelt I; Min JL; Bos S; Riyazi N; Houwing-Duistermaat JJ; van der Wijk HJ; Kroon HM; Nakajima M; Ikegawa S; Uitterlinden AG; van Meurs JB; van der Deure WM; Visser TJ; Seymour AB; Lakenberg N; van der Breggen R; Kremer D; van Duijn CM; Kloppenburg M; Loughlin J; Slagboom PE
    Hum Mol Genet; 2008 Jun; 17(12):1867-75. PubMed ID: 18334578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.